NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent wit ...

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent wit ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE base editor ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE base editor ...

Cellectis S.A. (CLLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a ch ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single point mutati ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single point mutati ...

财务数据和关键指标变化 - 公司现金、现金等价物、受限现金和定期存款于2024年3月31日为1.43亿美元,较2023年12月31日的1.56亿美元减少1300万美元 [29] - 公司认为其现金和现金等价物将足以为其运营提供资金至2026年,即至少12个月 [31] - 2024年第一季度归属于Cellectis股东的合并净收益为560万美元,每股0.08美元收益,而2023年同期为3010万美元亏损,每股0.58美元亏损 [32] - 2024年第一季度归属于Cellectis股东的经调整合并净收益为650万美元,每股0.09美元收益,而2023年同期为2810万美元亏损,每股0.55美元亏损 [34] 各条业务线数据和关键指标变化 - BALLI-01试验中,UCART22-P2制造的细胞比UCART22-P1更有效 [19][20][21][22] - NatHaLi-01试验中,UCART20x22在3例患者中均有反应,包括1例部分代谢反应和2例完全代谢反应 [23][24][25] - AMELI-01试验正在继续推进,正在以氟达拉滨、环磷酰胺和阿仑单抗淋巴细胞清除的2剂方案给患者输注 [26] 各个市场数据和关键指标变化 - 公司在美国和欧洲(法国和西班牙)开设了NatHaLi-01试验的临床试验点 [52] 公司战略和发展方向及行业竞争 - 公司将继续专注于推进自有的BALLI-01、NatHaLi-01和AMELI-01临床试验,同时与阿斯利康合作开发下一代基因编辑细胞和基因疗法 [13] - 公司相信基因编辑细胞和基因疗法将在多个治疗领域革新医疗,未来将成为分子医学的重要组成部分 [39] - 阿斯利康现持有公司约44%的股本和30%的表决权,并已委派两名董事加入公司董事会 [12] 管理层对经营环境和未来前景的评论 - 公司对与阿斯利康的战略合作和投资感到兴奋,相信这将有助于开发下一代细胞和基因疗法 [8][38][39] - 公司有信心推进自有的三项临床试验,并继续开发前期管线 [13][38][39] 其他重要信息 - 公司任命Arthur Stril为临时首席财务官,接替Bing Wang [14][15][16] - 阿斯利康于2024年5月3日追加投资1.4亿美元,持有公司约44%的股本和30%的表决权 [9][10][11][12] 问答环节重要的提问和回答 问题1 **Gena Wang 提问** - 阿斯利康合作对公司战略有何影响?公司制造能力是否可供阿斯利康使用?未来数据更新时间表如何? [42][43][44][47] **Arthur Stril 和 Mark Frattini 回答** - 自有管线战略未变,仍在大力推进UCART22、UCART20x22和UCART123 [43][44][47] - 阿斯利康可能会利用公司的制造能力,这是其感兴趣的一个原因 [44][45] - 预计2024年底将公布UCART22和UCART20x22的数据更新 [47][48] 问题2 **Dev Prasad 提问** - UCART20x22目前有多少活跃临床试验点?是否能在2024年底确定推荐剂量? [51] **Mark Frattini 回答** - 在美国和欧洲(法国和西班牙)都有活跃的临床试验点 [52] - 计划在2024年底前完成剂量递增阶段,届时将确定推荐剂量 [52][53] 问题3 **Salveen Richter 提问** - 2024年各项目的数据更新时间表和预期 [55] **Mark Frattini 回答** - UCART22和UCART20x22将在2024年底完成剂量递增阶段并公布数据 [57][58] - UCART123正在以2剂方案给患者输注,将在有足够数据时公布 [58]

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting is avail ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participatio ...